Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Coronary artery thrombolytic agent for acute myocardial infarction

A technology for acute myocardial infarction and coronary arteries, applied in the field of coronary thrombolytic agents and acute myocardial infarction, can solve the problems of poor curative effect of intravenous thrombolysis, many bleeding complications, and large surgical trauma, so as to reduce the occurrence of no-reflow rate, low bleeding complications, and high drug concentration

Inactive Publication Date: 2016-03-16
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the curative effect of intravenous thrombolysis is poor, and there are many bleeding complications; even if thrombus aspiration is used during PCI, there are still a large number of microthrombi that cannot be removed by mechanical therapy; the risk of CABG in the acute stage of MI is high, and the surgical trauma is large

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Coronary artery thrombolytic agent for acute myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] This comparative example provides a coronary thrombolytic agent for acute myocardial infarction, which is composed of the following components: tirofiban 0.5mg; bivalirudin 5mg; tenecteplase 3mg; sodium nitroprusside 0.4mg; Unfractionated heparin 0.0032mg; dilute to 10ml with normal saline.

Embodiment 2

[0027] This comparative example provides a coronary thrombolytic agent for acute myocardial infarction, which consists of the following components: tirofiban 2mg; bivalirudin 5mg; tenecteplase 3mg; sodium nitroprusside 0.4mg; ordinary Heparin 0.0032mg; dilute to 10ml with saline.

Embodiment 3

[0029] This comparative example provides a coronary thrombolytic agent for acute myocardial infarction, which is composed of the following components: tirofiban 0.5mg; bivalirudin 10mg; tenecteplase 3mg; sodium nitroprusside 0.4mg; Unfractionated heparin 0.0032mg; dilute to 10ml with normal saline.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a coronary artery thrombolytic agent for acute myocardial infarction. The coronary artery thrombolytic agent is prepared from, by weight, 0.5-2 parts of tirofiban, 5-10 parts of bivalirudin, 3-5 parts of tenecteplase, 0.4 part of sodium nitroprusside, 0.0032 part of unfractionated heparin and the balance normal saline, and the normal saline is used for diluting the mixture to obtain the volume which is 10 times of the original volume. Researches show that great advantages are brought when antiplatelet and anticoagulant drugs are administrated in a coronary artery based on PCI treatment, local drug concentration is high according to drug administration in the coronary, the needed thrombolytic drug dosage is small, thrombolysis is fast, the success rate is high, and few of hemorrhagic complications are caused. The coronary artery thrombolytic agent is used in cooperation with the intranperative radiography or intracavity radiological technology, thrombus changes can be dynamically monitored in real time, the best microthrombus dissolving effect is achieved, the PCI intraoperative no-reflow occurrence rate is lowered, and the prognosis of a patient is significantly improved.

Description

Technical field [0001] The invention belongs to the field of medicinal solutions applied to the body, and relates to acute myocardial infarction, and in particular to a coronary artery thrombolytic agent for acute myocardial infarction. Background technique [0002] The main cause of acute myocardial infarction (myocardial infarction, MI) is coronary artery occlusion caused by unstable plaque rupture and acute thrombosis, causing partial myocardial necrosis due to severe and persistent ischemia. The existing treatment methods include intravenous thrombolysis, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) and so on. However, intravenous thrombolysis has poor efficacy and many bleeding complications. Even if thrombus aspiration is used during PCI, there are still a large number of microthrombi that cannot be removed by mechanical treatment. CABG in the acute phase of MI has a high risk and large surgical trauma. Therefore, it is urgent to find new t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/48A61K38/10A61P9/10A61P7/02A61K31/4465A61K33/26A61K31/727
Inventor 孙冬冬张磊王成果李妍王海昌陈江红魏丽萍
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com